Brief: Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
28/02/2024 13:27
Feb 28 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS ANNOUNCES PUBLICATION OF CTX-8371
PRECLINICAL DATA IN ONCOIMMUNOLOGY, ITS BISPECIFIC ANTIBODY
CHECKPOINT INHIBITOR, NOW ADVANCING TO FIRST-IN-HUMAN CLINICAL
TRIAL
Source text for Eikon: ID:nGNXCnFLb
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback